T. Rowe Price Associates
XENT

T. Rowe Price Associates’s Intersect ENT, Inc XENT Stock Holding History

T. Rowe Price Associates’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-813,691
Closed -$11M – 2645
2020
Q2 		$11M Sell
813,691
-3,689
-0.5% -$42.9K ﹤0.01% 1275
2020
Q1 		$9.69M Buy
+817,380
New +$18.1M ﹤0.01% 1231
2015
Q2 		– Sell
-226,416
Closed -$5.85M – 2567
2015
Q1 		$5.85M Buy
+226,416
New +$5.18M ﹤0.01% 1448

Other funds holding XENT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

T. Rowe Price Associates's XENT Position: Q3 2020 in Review

T. Rowe Price Associates sold out of Intersect ENT, Inc (XENT) in Q3 2020, closing a stake of 813,691 shares — an estimated $11M sold.

T. Rowe Price Associates first reported a position in XENT in Q1 2015 and held it in 3 quarters. The position peaked at $11M in Q2 2020. 112 funds tracked by Wall St. Rank hold XENT as of Q3 2020.

  • T. Rowe Price Associates reported no remaining Intersect ENT, Inc position as of Q3 2020 after selling out during the quarter.
  • T. Rowe Price Associates sold 813,691 Intersect ENT, Inc shares in Q3 2020, an estimated $11M.
  • T. Rowe Price Associates first reported a position in Intersect ENT, Inc in Q1 2015 and held it in 3 quarters.
  • T. Rowe Price Associates's Intersect ENT, Inc position peaked at $11M in Q2 2020.
  • 112 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q3 2020.

Based on T. Rowe Price Associates's 13F filing for Q3 2020, filed 16 Nov 2020.